Company: WHWK
Filing Date: 2025-03-28
Form Type: 10-K
Source: 0001628280-25-015269
Chunk: 313

Company: Whitehawk Therapeutics, Inc.
Filing Date: 2025-03-28
Form: 10-K
Item: Item 8
Chunk 313
---
142 Net loss— — — — (65,765)(65,765)Balance at December 31, 202324,554 $2 $374,129 $27 $(268,963)$105,195 Share-based compensation expense— — 10,839 — — 10,839 Issuance of common stock in conjunction with vesting of restricted stock units33 — — — — — Issuance of shares under the employee stock purchase plan94 — 146 — — 146 Unrealized loss on investments, net of tax— — — (11)— (11)Net loss— — — — (63,691)(63,691)Balance at December 31, 202424,681 $2 $385,114 $16 $(332,654)$52,478 

The accompanying notes are an integral part of these consolidated financial statements.

119

WHITEHAWK THERAPEUTICS, INC.

Consolidated Statements of Cash Flows

(in thousands)

Year Ended December 31,20242023Cash flows from operating activities:Net loss$(63,691)$(65,765)Adjustments to reconcile net loss to net cash used in operating activities:Share-based compensation expense10,839 11,954 Amortization of premiums and discounts on short-term investments, net(1,301)(3,136)Non-cash interest expense— 58 Non-cash lease expense460 461 Depreciation and amortization expense193 169 Changes in operating assets and liabilities:Accounts receivable(415)(3,626)Inventory1,116 (3,265)Prepaid expenses and other current assets2,814 3,603 Other non-current assets518 518 Operating lease liabilities, net(512)(502)Accounts payable and accrued liabilities(9,773)(132)Other liabilities202 — Net cash used in operating activities(59,550)(59,663)Investing activities:Purchases of property and equipment(1,654)(3,972)Purchases of short-term investments(36,482)(64,439)Maturities of short-term investments63,338 151,617 Net cash provided by investing activities25,202 83,206 Financing activities:Issuance of common stock upon exercise of stock options—